We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Maryland-based Emergent BioSolutions has signed an $87 million contract with AstraZeneca to support development and production of the UK company’s COVID-19 vaccine, one of the leading candidates in the global race for an effective product. Read More
The kinase inhibitor is approved for treatment of rheumatoid arthritis in adults whose disease is not well-controlled using other medications. Read More
The company is scaling production to have hundreds of thousands of preventative doses or tens of thousands of larger treatment doses per month by the end of August. Read More
Researchers funded by the National Institutes of Health (NIH) are evaluating drugs doctors are using to treat COVID-19 in infants, children and adolescents. Read More
The U.S. government is planning to launch phase 3 trials of three COVID-19 vaccine candidates, starting with Moderna’s as soon as next month, followed by AstraZeneca’s AZD1222 in August, and a Johnson & Johnson candidate in September. Read More
Aimmune Therapeutics said that 80 percent of allergic patients in a trial of its oral immunotherapy Palforzia (peanut allergen powder-dnfp) were desensitized to peanut proteins. Read More
AstraZeneca has licensed six monoclonal antibodies from Vanderbilt University and plans to advance the most promising ones for prevention and treatment of COVID-19. Read More